Trevena Inc. is planning to raise $40 million through a public stock offering.
The King of Prussia, Pa., biopharmaceutical company, went public earlier this year through a $64.75 million IPO completed in February.
Trevena's focus is on developing the next generation of medicines that target G-protein coupled receptors, also known as GPCRs. GPCRs are a large family of cell surface receptors that trigger signaling pathways linked to cellular function and disease processes.
Help employers find you! Check out all the jobs and post your resume.
Trevena's focus is on developing the next generation of medicines that target G-protein coupled receptors, also known as GPCRs. GPCRs are a large family of cell surface receptors that trigger signaling pathways linked to cellular function and disease processes.
Help employers find you! Check out all the jobs and post your resume.
